Table 2 Patient characteristics and treatment outcome
N = 9 | ||
|---|---|---|
Sex | Male | 6 (66.7%) |
Female | 3 (33.3%) | |
Diagnosis | Malignant melanoma | 3 (33.3%) |
Esophagus carcinoma | 1 (11.1%) | |
Thoracic aortic aneurysm | 1 (11.1%) | |
Penile carcinoma | 1 (11.1%) | |
Erosive esophagitis induced esophageal stenosis | 1 (11.1%) | |
Cutaneous Merkel cell carcinoma | 1 (11.1%) | |
Chondrosarcoma | 1 (11.1%) | |
Surgery | Inguinal lymphadenectomy | 5 (55.6%) |
Thoracic-abdominal esophagus resection and lymphadenectomy | 2 (22.2%) | |
Descending aorta replacement | 1 (11.1%) | |
Bone tumour resection | 1 (11.1%) | |
Location of the lymphatic leakage | Chylothorax | 3 (33.3%) |
Inguinal lymphatic fistula | 3 (33.3%) | |
Lymphatic fistula at the thigh | 3 (33.3%) | |
Other treatment to cure LL except for the conservative therapy before TL | None | 5 (55.6%) |
Surgical revision | 3 (33.3%) | |
Doxycycline instillation | 1 (11.1%) | |
Clinical outcomes of the ALVS treatment | Clinical success | 8 (88.9%) |
Clinical failure | 1 (11.1%) | |
Salvage treatment after the clinical failure of the ALVS | Surgical revision | 1 (11.1%) |
Age (years) | 63 ± 10 (49–81) | |
Daily chyle/lymph output (mL/d) | 541 ± 545 (100–1,500) | |
Interval between surgery and TL (days) | 27 ± 18 (13–70) | |
Volume of iodised oil injected in TL (mL) | 11.8 ± 5.0 (5.0–20.0) | |
Interval between TL and ALVS (days) | 12 ± 8 (3–28) | |
Volume of 95% ethanol injected in ALVS (mL) | 2.7 ± 1.3 (1.0–5.0) | |
Interval between ALVS and the cure of LL (days) | 8 ± 6 (1–20) | |